One of the key challenges in cancer precision medicine is finding robust biomarkers of drug response. Patient-derived tumor xenografts (PDXs) have emerged as reliable preclinical models since they better recapitulate tumor response to chemo-and targeted therapies. However, the lack of standard tools poses a challenge in the analysis of PDXs with molecular and pharmacological profiles. Efficient storage, access and analysis is key to the realization of the full potential of PDX pharmacogenomic data. We have developed Xeva (XEnograft Visualization & Analysis), an open-source software package for processing, visualization and integrative analysis of a compendium of in vivo pharmacogenomic datasets. The Xeva package follows the PDX minimum information (PDX-MI) standards and can handle both replicate-based and 1x1x1 experimental designs. We used Xeva to characterize the variability of gene expression and pathway activity across passages. We found that only a few genes and pathways have passage specific alterations (median intraclass correlation of 0.53 for genes and positive enrichment score for 92.5% pathways).
INTRODUCTION
Preclinical models are vital for investigating disease biology and therapeutics, constituting essential tools for translational research and drug development. In cancer research, immortalized cell lines are the most used preclinical models because of their low cost, flexibility and the existence of assays enabling genetic and chemical screen in a high-throughput manner.
These in vitro pharmacogenomic studies led to the discovery of many clinically-approved biomarkers for anticancer therapies 1 . Recent large-scale in vitro drug screening datasets [2] [3] [4] , coupled with rigorous computational analysis pipelines [5] [6] [7] [8] [9] [10] [11] hold the promise to find new drug response biomarkers. However, the cell line models suffer from multiple limitations. Although they are derived from patient tumors, they have evolved to survive in artificial culture conditions resulting in major alterations at the genomic level [12] [13] [14] [15] [16] [17] . These in vitro models also lack the tumor heterogeneity and three-dimensional structure of the origin patient tumor 15,18-20 .
To create cancer models that better recapitulate the tumor molecular features and drug response, the pharmaceutical industry and academia massively invested in the development of patient-derived xenografts (PDXs) 21 , which enable engraftment of human tumors in animal models [22] [23] [24] [25] [26] [27] [28] . PDXs are created by subcutaneous or orthotopic engraftment of the cancerous tissues or cells from patients' tumors into immunodeficient mice. Once established, these tumors can be passed from mouse to mouse, leading to consecutive "passages" of the initial tumor cells.
PDX models are being generated and distributed by several academic groups, research institutes and commercial organizations. This makes it challenging to find PDX models with specific characteristics such as a model with a specific mutation. Therefore, catalogues of PDX models (e.g. PDXFinder 29 , EurOPDX 30 and PRoXe 31 ) are being developed which contain relevant information and provide links to model acquisition. Furthermore, as PDXs are becoming the gold standard model for preclinical studies, better data standardization and analysis platforms are required to ensure consistency and reproducibility in PDX-based analysis.
Recently, a robust standard called PDX models minimal information (PDX-MI) has been proposed 32 for reporting and quality assurance for PDX models. However, management, analysis and visualization of the PDX-based drug screening and genomic data still constitute major challenges.
Here we present Xeva (Xenograft Visualization and Analysis), a computational package enabling storage, access and analysis of in vivo pharmacogenomics data. The Xeva toolbox facilitates biomarker discovery in PDX-based pharmacogenomic data. It implements class structure to manage and connect PDX-based drug screening data to the genomic features of the corresponding tumor. It provides functions for PDX data analysis, including multiple metrics to summarize drug response for tumor growth curves. Xeva provides functions to compute the association between genomic features and response to a drug in PDXs (gene-drug association).
Different response metrics for the PDX growth curve can be used as outcome to identify novel gene-drug associations that can act as drug companion tests. Using the Xeva platform, we analyzed gene expression of PDXs across passages and demonstrated that activity patterns of the majority of the genes and pathways are stable across different PDX passages. Our analysis shows that PDXs maintain the vast majority of the pathway activity across passages. We identified multiple pathways significantly associated with anticancer drug response, including known and new biomarkers based on gene expression, copy number aberrations (CNAs) and mutations. Our results support the value of large-scale PDX-based drug screening for biomarker discovery using the integrative pharmacogenomic analysis pipelines implemented in the Xeva computational platform.
MATERIALS AND METHODS

Processing of Pharmacogenomic Data
Gene expression data, PDX passages and tissue information were obtained from the Gene Expression Omnibus series GSE78806. Gene expression profiles were normalized with the RMA algorithm in the Affy package (version 1.58.0) in Bioconductor 33 . PDX passages and tissue information were curated manually. Molecular profiles including mutation, CNA, gene expression and pharmacological profiles were obtained from the publication Gao et al . 28 . Data were processed using R statistical software ( http://www.r-project.org/ ). The final dataset contains 3,470 unique PDX models tested across 57 treatments and derived from 191 patients spanning across 5 different cancer types.
Implementation
PDX pharmacogenomic experiments aim to investigate how tumor volume changes in in vivo
models with respect to time, with and without drug treatment. The corresponding metadata, such as drug dose, number of days from tumor implantation to treatment start or reason for stopping the experiment (e.g. whether mice died because of complications or were sacrificed due to maximal allowed tumor volume reached), are crucial factors for downstream analysis. In the Xeva platform, we have developed the XevaSet class to effectively store pharmacological response (time vs. tumor volume) of PDXs along with metadata related to the experiments and molecular data. Furthermore, to store individual PDX (mouse) model data, we have implemented the pdxModel class, which provides slots for PDX-MI variables, along with time vs.
tumor volume data. Detailed schematics of the XevaSet and pdxModel classes are shown in
Supplementary Figure S2 and S3, respectively. XevaSet object can contain multimodal genomic data, which are linked to individual xenograft models and their pharmacological profiles. Data can be subsetted by metadata and experimental factors, such as tumor types or drug names.
PDX Experiment Design
In vivo evaluation of drug sensitivity in cancer xenografts has traditionally used experimental approaches incorporating multiple animals (five to ten) replicates for each control and treatment arm. This experimental design allows the assessment of the variability in the PDX drug response across individual animals 34 . However, scaling this strategy for high-throughput drug screening is costly and requires the use of a large number of experimental animals. To increase the number of compounds being tested, reduce cost and permit the use of fewer animals to provide essential data 35 , a simpler "1x1x1" experimental design for PDX clinical trial (PCT) has been proposed 28, 36 . In this design, each compound is tested in only one PDX model from each patient (Supplementary Figure S9) . Though the 1x1x1 experiment design allows high-throughput screening at reduced cost, it is more prone to experimental errors due to lack of replications. Factors such as difference in the handling of mice or measurement errors in the tumor volume and biological variability in tumor growth rates between animals could significantly impact the results. We foresee that both experimental design strategies will co-exist, where the 1x1x1 experiment design will be used for population-level and high-throughput screening, while the replicate-based experiment design will be used for more focused studies where discrimination of small differences in drug response is a desired outcome. We therefore implemented functions to accommodate both experimental designs for data visualization and statistical analyses.
PDX Response Metrics
Given the lack of consensus regarding the best summary metrics to estimate in vivo drug 
where V denotes tumor volume, T denotes time. The intercept and slope are denoted by α and β, respectively. Subsequently, the angle was computed using inverse tangent of regression line slope as:
The tumor growth inhibition (TGI) is defined as:
where VC and VT are the median of control and treated growth curve respectively at the end of the study. VC 0 and VT 0 indicate the initial tumor volume for control and treated growth curve respectively.
The best average response (BAR) metric for each PDX model is defined as follows:
At each time point t, the normalized change in tumor volume is computed as
Next, for each time t, the running average of from t=0 to t, was calculated. BAR is defined V Δ t as the minimum of this running average (at ). The minimum value of (at 0 days t ≥ 1 V Δ ) defines as best response (BR). Using these, the mRESIST metric for PDX is 0 days t ≥ 1 computed as:
• complete response (CR) : BR < -95% and BAR < -40%
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• partial response (PR) : BR < -50% and BAR < -20%
• stable disease (SD) : BR < 35% and BAR < 30%
• progressive disease (PD) : not otherwise categorized
Visualization of In Vivo drug Screening Data
Several Xeva functions enable multi-faceted visualization and exploration of the PDX data. The plotPDX function displays tumor growth curves, plotting time versus tumor volume data for a patient-drug pair or matched control and treatment PDX models (called batch). The waterfall function visualizes population-level response for a given set of PDXs. Similarly, plotmRECIST displays mRECIST-based drug response as a heatmap, with drugs along heatmap rows and PDXs along columns. Heatmap cells are colored according to the mRECIST value for the corresponding PDX-drug pair.
Gene Expression Consistency Analysis
We calculated the Pearson correlation coefficient between pairs of samples belonging to the same lineage using the L1000 landmark gene set 41 . For comparison, we also computed the Pearson correlation coefficient between all possible pairs of samples that do not belong to the same lineage. For genes, we computed the intra-class correlation coefficient (ICC) using the psych package (version 1.8.4). For a particular gene, in each sample we computed its rank by sorting the expression values. The rank of genes along with passage information is used for ICC calculation. ICC values of the genes were used to perform gene set enrichment analysis on the MSigDB hallmark gene sets 42 and Reactome pathway database 43 , which contains gene sets associated with specific pathways.
Pathways and Gene-Drug Association Analysis
We computed the association between a molecular feature and response to a drug across PDXs (commonly referred to as gene-drug association or drug response predicting biomarker). The gene-drug association was assessed separately for all three available molecular features, i.e. gene expression, CNA and gene mutation. The response of PDXs to a drug treatment is defined using best average response (BAR).
The association between genomic feature and PDX response was computed using non-parametric measure of association, concordance index (CI) 44 and its equivalent Somers'
Dxy rank correlation (DXY) 45 . The CI represents the probability that two variables will rank a random pair of samples the same order. The DXY is equivalent to rescaling the CI values between -1 and 1 using (CI -0.5) * 2 .
For each drug, we compiled a list of potential biomarkers using OncoKB 46 and literature curation. We adjusted the p-value using FDR for drug combinations and drugs with multiple potential biomarkers. Univariate gene-drug associations were calculated for three different molecular profiling modalities that are gene expression, copy number variation and mutation.
For drug-pathway association analysis, the Reactome pathway database 43 was used. We created a subset of the pathway database by selecting only the gene-sets containing at least one potential drug target and containing less than 300 genes. We also grouped the drugs in different classes according to their genomic target. In total we selected 94 pathways related to 57 drugs and drugs were classified into 11 classes. Pathway analysis was performed using the R Piano package (version 1.20.1) 47 . Circos plot was used to visualize the drug-pathway association 48 .
Research Reproducibility
The source code of the Xeva package is open source under licence GPLv3 and available from GitHub ( https://github.com/bhklab/Xeva ). A complete software environment containing necessary data and code to reproduce the analysis and figures described in the manuscript is available at Code Ocean .
RESULTS
Xeva Follows PDX-MI Standards To Store Pharmacogenomic Data
We designed XevaSet , a new object class enabling integration of molecular and Heatmaps representing the mRECIST data cutaneous melanoma, colorectal cancer, gastric 10 cancer, non-small-cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma can be found in Supplementary Figures S4 to S8 , respectively. Visualization of PDX growth curves is an essential part of data quality control and analysis. Tumor growth curves for individual PDX models and for matched control-treatment models can be plotted using the plotPDX function.
Examples of PDX tumor growth curves in control (untreated) and treatment (paclitaxel) conditions are shown in Figure 1d- To identify pathways that are enriched with unstable genes, we performed a gene set enrichment analysis with the genome-wide ranking of genes based on their stability across passages (ICC values; Figure 4 and Supplementary File 3). We found that post-transcriptional mRNA processing pathways such as mRNA 3′end processing and mRNA splicing are enriched with unstable genes. It is well established that during proliferation and differentiation, cells adjust the mRNA and protein level by controlling the post-transcriptional mRNA processing pathways [62] [63] [64] . Therefore the instability of these post-transcriptional mRNA processing pathways might be attributed to the tumor growth in the PDX. Targeting these pathways using a drug in PDXs might result in inconsistent response at different passages.
In Vivo Biomarker Discovery
One of the main goals of pharmacogenomic studies is to find genomic biomarkers for drug response prediction. We evaluated the association between a molecular feature and response to a given drug (gene-drug association) in PDXE 28 data. The PDXE data consists of a We employed Xeva to identify biomarkers for drug response prediction by computing gene-drug associations for drugs in the PDXE data and their corresponding known biomarker genes defined using OncoKB resource 46 . For the analysis, a PDX's response to a drug is defined using best average response (BAR) and association was computed using concordance 
DISCUSSION
Patient-derived xenografts are valuable models for cancer modeling and pharmacogenomic analysis. However, the translational potential of PDX preclinical models is highly dependent on the tools and techniques to processing and analyzing the data.
Computational tools that enable standardized processing are thus an integral part of this line of research, and harmonized approaches can provide the community with accessible means for the analysis. The Xeva platform allows researchers to visualize and analyze the complex pharmacogenomic data generated during in vivo drug screening studies. The key strengths of the Xeva platform is its ability to store all metadata from a PDX experiment, link genomic data to corresponding PDX models and provide user friendly functions for analysis.
In a recent study, Ben-David et. al . 61 analyzed changes in CNAs during PDX passaging using experimental and computational inferred copy number alterations (CNAs) from gene expression profiles. In our study, we found that the multiple known biomarkers predictive of drug response can be identified in the large Novartis PDXE dataset. Notably, the dataset used in this study has the 1x1x1 PDX experiment design (Supplementary Figure S9) . Thus our results demonstrate that the 1x1x1 PDX experiment design is an adequate way to discover drug response predicting biomarkers at the population level. While the 1x1x1 experiment design is a cost-and animal-resource efficient way to find biomarkers, using Xeva, we have found cases where control (untreated) mice show a partial response (PR) or tumor shrinkage. Possible causes of such early tumor shrinkage might include experimental error, handling glitches or genetic properties of the tumor. In a 1x1x1 experiment design, lack of replicates makes it impossible to 16 decipher the exact cause. Visualization and analysis of PDX response data using Xeva provides an efficient way to recognize such cases.
For biomarker discovery analysis, treatment response in PDXs is defined by the best average response (BAR) 28 . This metric of treatment response provides a continuous value, however it does not take into account the control arm of the PDX experiment. As PDX-based pharmacogenomics gains popularity, standardized metrics to define response are required, thereby taking into account the control arm of the PDX experiments. Such methods will also improve the biomarker discovery process. Xeva provides a standard tool for comparison of different PDX response metrics.
The Xeva package enables easy and efficient analysis of the PDX-based pharmacogenomic data. Xeva includes functions to link molecular features to drug response, therefore providing a unified framework for analysis and development of biomarkers of drug response.
CONCLUSION
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